logo
logo
AI

Discover the World’s Fastest Business Insights

Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.

Vigil Neuroscience Launches with $50 Million in Financing to Develop Microglia-based Therapeutics for Neurodegenerative Diseases

Vigil Neuroscience Launches with $50 Million in Financing to Develop Microglia-based Therapeutics for Neurodegenerative Diseases

12/08/20, 1:05 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgcambridge
Money raised
$50 million
Vigil Neuroscience, a new biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, launched today with $50 million Series A financing. Atlas Venture co-founded, seeded and incubated Vigil with late pre-clinical-stage assets in-licensed from Amgen Inc., who will remain a key shareholder in the company. The Series A round was co-led by Atlas Venture and Northpond Ventures and includes participating investors Hatteras Venture Partners and Alexandria Venture Investments. The company is led by industry veteran Ivana Magovčević-Liebisch, PhD, JD as President and Chief Executive Officer.

Company Info

Company
Vigil Neuroscience
Location
cambridge, maryland, united states
Additional Info
Vigil Neuroscience is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families. www.vigilneuro.com
G2 High Performer Badge

Never Miss an Opportunity: Your #1 Sales Intelligence Tool

Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.